Market Closed -
Other stock markets
|
Pre-market 12:02:08 pm | |||
82.8 EUR | -1.95% | 82.78 | -0.03% |
02/04 | Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment | MT |
12/03 | Rovi, Partners to Form Entity for Advanced Therapies R&D | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+37.54% | 4.63B | |
+33.43% | 700B | |
+26.43% | 569B | |
-5.12% | 358B | |
+19.59% | 330B | |
+4.89% | 287B | |
+14.32% | 236B | |
+5.79% | 202B | |
-9.49% | 197B | |
+4.26% | 161B |
- Stock Market
- Equities
- ROVI Stock
- News Laboratorios Farmaceuticos Rovi, S.A.
- Transcript : Laboratorios Farmaceuticos Rovi, S.A., 2022 Earnings Call, Feb 21, 2023